Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)EBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Bioventus (BVS) Receivables - Other (2020 - 2025)

Bioventus filings provide 6 years of Receivables - Other readings, the most recent being $177000.0 for Q4 2025.

  • On a quarterly basis, Receivables - Other rose 132.89% to $177000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $177000.0, a 132.89% increase, with the full-year FY2025 number at $177000.0, up 132.89% from a year prior.
  • Receivables - Other hit $177000.0 in Q4 2025 for Bioventus, up from $76000.0 in the prior quarter.
  • In the past five years, Receivables - Other ranged from a high of $50.0 million in Q4 2021 to a low of $76000.0 in Q4 2024.
  • Median Receivables - Other over the past 5 years was $257000.0 (2023), compared with a mean of $8.2 million.
  • Biggest five-year swings in Receivables - Other: surged 225.61% in 2022 and later tumbled 70.43% in 2024.
  • Bioventus' Receivables - Other stood at $82000.0 in 2021, then surged by 225.61% to $267000.0 in 2022, then fell by 3.75% to $257000.0 in 2023, then crashed by 70.43% to $76000.0 in 2024, then surged by 132.89% to $177000.0 in 2025.
  • The last three reported values for Receivables - Other were $177000.0 (Q4 2025), $76000.0 (Q4 2024), and $6.5 million (Q3 2024) per Business Quant data.